Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

How the rich get richer.

Mike Rossner, Ira Mellman

    The Journal of Experimental Medicine
    |June 20, 2007
    PubMed
    Summary
    This summary is machine-generated.

    Howard Hughes Medical Institute (HHMI) is offering financial incentives to a commercial publisher. This is for providing public access to research, a service already common among nonprofit scientific publishers.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Tim-3-targeted vaccines overcome tumor immunosuppression and reduce cDC1 dependence to elicit potent anti-tumor immunity.

    Proceedings of the National Academy of Sciences of the United States of America·2026
    Same author

    Clonal hematopoiesis is associated with reduced response to atezolizumab in non-small cell lung cancer.

    Journal for immunotherapy of cancer·2025
    Same author

    RNA neoantigen vaccines prime long-lived CD8<sup>+</sup> T cells in pancreatic cancer.

    Nature·2025
    Same author

    Different PD-L1 Assays Reveal Distinct Immunobiology and Clinical Outcomes in Urothelial Cancer.

    Cancer immunology research·2025
    Same author

    Publisher Correction: TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted antitumor T cells by facilitating co-stimulation.

    Nature cancer·2025
    Same author

    Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial.

    Nature medicine·2025

    Area of Science:

    • Biomedical research funding
    • Scholarly publishing models
    • Open access initiatives

    Background:

    • The Howard Hughes Medical Institute (HHMI) plans to provide monetary rewards to a commercial publisher.
    • This funding is contingent upon the publisher offering public access to research content.
    • Many nonprofit publishers already provide similar public access without direct financial incentives from funding bodies.

    Discussion:

    • The study examines the implications of HHMI's new funding model for commercial scientific publishing.
    • It questions the necessity of financial rewards for commercial entities to achieve public access goals.
    • The current landscape of nonprofit publishing offers a benchmark for evaluating the effectiveness of this initiative.

    Key Insights:

    • HHMI's financial incentives may not be novel in achieving public access for research.

    Related Experiment Videos

  • The initiative could potentially reshape publisher-funder relationships in scientific communication.
  • Evaluating the long-term impact on publishing economics and research dissemination is crucial.

    • Outlook:

    • Future research should analyze the sustainability and scalability of such funding models.
    • Investigating the influence on research accessibility and the broader scientific community is recommended.
    • Assessing the potential for increased competition or consolidation within the scientific publishing market.